DK3179393T3 - Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft - Google Patents

Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft Download PDF

Info

Publication number
DK3179393T3
DK3179393T3 DK16191856.0T DK16191856T DK3179393T3 DK 3179393 T3 DK3179393 T3 DK 3179393T3 DK 16191856 T DK16191856 T DK 16191856T DK 3179393 T3 DK3179393 T3 DK 3179393T3
Authority
DK
Denmark
Prior art keywords
prostate
algorm
test
determining
gene expression
Prior art date
Application number
DK16191856.0T
Other languages
English (en)
Inventor
Steve Shak
Mark Lee
William Novotny
Tara Maddala
Michael Crager
Diana Cherbavaz
Robert Pelham
Carl L Millward
Dejan Knezevic
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Application granted granted Critical
Publication of DK3179393T3 publication Critical patent/DK3179393T3/da

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Complex Calculations (AREA)
DK16191856.0T 2012-01-31 2013-01-28 Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft DK3179393T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261593106P 2012-01-31 2012-01-31
US201261672679P 2012-07-17 2012-07-17
US201261713734P 2012-10-15 2012-10-15
EP13743785.1A EP2809812A4 (en) 2012-01-31 2013-01-28 GENE EXPRESSION PROFILE ALGORITHM AND PROSTATE CANCER PROGNOSTIC DETERMINATION TEST

Publications (1)

Publication Number Publication Date
DK3179393T3 true DK3179393T3 (da) 2020-07-27

Family

ID=48870540

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16191856.0T DK3179393T3 (da) 2012-01-31 2013-01-28 Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft

Country Status (14)

Country Link
US (3) US8725426B2 (da)
EP (3) EP2809812A4 (da)
JP (3) JP6351112B2 (da)
AU (3) AU2013215448B2 (da)
CA (1) CA2863040C (da)
CO (1) CO7051010A2 (da)
DK (1) DK3179393T3 (da)
ES (1) ES2812105T3 (da)
HK (1) HK1201881A1 (da)
IL (3) IL233709A (da)
MX (3) MX351626B (da)
NZ (2) NZ627887A (da)
SG (3) SG10201912312YA (da)
WO (1) WO2013116144A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912312YA (en) * 2012-01-31 2020-02-27 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
EP3084426B1 (en) * 2013-12-18 2020-04-15 Pacific Biosciences Of California, Inc. Iterative clustering of sequence reads for error correction
CN103695560B (zh) * 2014-01-09 2016-09-14 上海交通大学医学院附属瑞金医院 Ppp1r12a基因在结直肠癌化疗疗效判断和检测试剂盒中的应用
AU2015206336B2 (en) * 2014-01-16 2020-01-23 Illumina, Inc. Gene expression panel for prognosis of prostate cancer recurrence
US20170016903A1 (en) * 2014-02-28 2017-01-19 The Johns Hopkins University Genes encoding secreted proteins which identify clinically significant prostate cancer
BR112017007962A2 (pt) 2014-10-24 2018-01-23 Koninklijke Philips Nv método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
WO2016062892A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
BR112017007965A8 (pt) 2014-10-24 2022-11-08 Koninklijke Philips Nv Método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit
CN104880565A (zh) * 2015-05-04 2015-09-02 贵州省人民医院 Zfp36前列腺癌预后诊断的检测试剂及其试剂盒
RU2721916C2 (ru) * 2015-05-29 2020-05-25 Конинклейке Филипс Н.В. Способы прогнозирования рака предстательной железы
KR20180082328A (ko) * 2015-05-29 2018-07-18 코닌클리케 필립스 엔.브이. 전립선 암 예측 방법
EP3318632B8 (en) * 2015-07-01 2022-12-14 Fujita Academy Marker for heterogeneity of cancer tissue, and use thereof
EP3334837B1 (en) 2015-08-14 2020-12-16 Koninklijke Philips N.V. Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression
WO2017062505A1 (en) * 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
WO2017127696A1 (en) * 2016-01-20 2017-07-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
EP3270163B1 (en) * 2016-07-15 2018-09-05 ProteoMediX AG Method of detecting proteins in human samples and uses of such methods
CN110506127B (zh) 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途
US11586674B2 (en) * 2016-12-28 2023-02-21 Khalifa University of Science and Technology Methods and systems for searching
SG11201906318WA (en) * 2017-02-13 2019-08-27 Genomic Health Inc Algorithms and methods for assessing late clinical endpoints in prostate cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3701532A1 (en) * 2017-10-27 2020-09-02 King Abdullah University Of Science And Technology A graph-based constant-column biclustering device and method for mining growth phenotype data
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502280A1 (en) * 2017-12-21 2019-06-26 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables
EP3743533A1 (en) * 2018-01-25 2020-12-02 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer
AU2019224025A1 (en) * 2018-02-22 2020-09-10 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN109001467A (zh) * 2018-07-20 2018-12-14 贵州省人民医院 一种用于前列腺癌的基因联合预后检测试剂及其制备方法
GB201816820D0 (en) * 2018-10-16 2018-11-28 Univ York Diagnostic method
EP3874274B1 (en) 2018-10-31 2024-01-03 Regents of the University of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
CN114222588A (zh) 2019-08-12 2022-03-22 雷杰纳荣制药公司 巨噬细胞刺激1受体(mst1r)变体及其用途
EP3901288A1 (en) * 2020-04-20 2021-10-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-gene expression assay for prostate carcinoma

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
AU766544B2 (en) 1998-06-06 2003-10-16 Genostic Pharma Limited Probes used for genetic profiling
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
ATE424457T1 (de) 2000-01-13 2009-03-15 Genentech Inc Menschliche stra6 polypeptide
WO2002031209A2 (en) 2000-10-13 2002-04-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Genes related to development of refractory prostate cancer
US20030087818A1 (en) 2001-02-02 2003-05-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002079411A2 (en) 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
US20030108963A1 (en) 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
US20100297657A1 (en) 2001-08-02 2010-11-25 The Regents Of The University Of Michigan Expression profile of prostate cancer
EP1451340B1 (en) 2001-11-09 2014-01-08 Life Technologies Corporation Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030148410A1 (en) 2001-12-10 2003-08-07 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
JP2005519606A (ja) 2002-03-14 2005-07-07 エグゾニ・テラピューティック・ソシエテ・アノニム ヒトカリクレイン−２及びカリクレイン−３のバリアント並びにそれらの使用
AUPS187002A0 (en) 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
AU2003274970A1 (en) 2002-09-10 2004-04-30 Guennadi V. Glinskii Gene segregation and biological sample classification methods
US7659062B2 (en) 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
WO2005008213A2 (en) 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
CA2565450C (en) 2004-05-07 2018-03-06 Gyorgy Petrovics Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
US20080318803A1 (en) 2004-05-27 2008-12-25 Vertex Pharmaceuticals Biomarkers for Monitoring Impdh Pathway Inhibition
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
CA2576624A1 (en) 2004-08-13 2006-03-16 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
WO2006110264A2 (en) 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
US20090186024A1 (en) 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
US8278038B2 (en) 2005-06-08 2012-10-02 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006287175A1 (en) 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2007072225A2 (en) 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
US7695913B2 (en) 2006-01-11 2010-04-13 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
ES2300176B1 (es) 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
US7914988B1 (en) * 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
WO2007149965A2 (en) 2006-06-22 2007-12-27 Wisconsin Alumni Research Foundation Stromal collagen in the diagnosis and characterization of breast cancer
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
US20080254481A1 (en) * 2006-11-13 2008-10-16 Invitrogen Corporation Methods and kits for detecting prostate cancer biomarkers
CA2680591A1 (en) 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2008133877A1 (en) * 2007-04-23 2008-11-06 California Institute Of Technology Inhibitors for steroid response elements and related methods
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
AU2009253675A1 (en) * 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US20090298082A1 (en) * 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
KR20110052627A (ko) 2008-07-16 2011-05-18 다나-파버 캔서 인스티튜트 인크. 전립선암과 관련된 시그너처 및 ｐｃ결정인자 및 그의 사용 방법
WO2010056993A2 (en) 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
EP2382331B1 (en) 2009-01-07 2016-06-08 Myriad Genetics, Inc. Cancer biomarkers
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
US20100303795A1 (en) 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
CA2767659C (en) 2009-07-08 2020-10-20 Worldwide Innovative Network Method for predicting efficacy of drugs in a patient
CA2776751C (en) * 2009-11-23 2019-07-02 Genomic Health, Inc. Methods to predict clinical outcome of cancer
WO2011085263A2 (en) 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
SG10201505769PA (en) 2010-07-27 2015-09-29 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
SG10201912312YA (en) * 2012-01-31 2020-02-27 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer

Also Published As

Publication number Publication date
EP3179393A2 (en) 2017-06-14
EP3739595A3 (en) 2021-01-27
MX366164B (es) 2019-07-01
CA2863040A1 (en) 2013-08-08
AU2013215448B2 (en) 2018-01-04
SG10201605210PA (en) 2016-08-30
US11011252B1 (en) 2021-05-18
IL233709A0 (en) 2014-09-30
IL262648A (en) 2018-12-31
JP6908571B2 (ja) 2021-07-28
HK1201881A1 (en) 2015-09-11
SG11201404390WA (en) 2014-08-28
IL233709A (en) 2017-09-28
EP3179393B1 (en) 2020-07-08
IL254255A0 (en) 2017-10-31
US8725426B2 (en) 2014-05-13
WO2013116144A1 (en) 2013-08-08
AU2013215448A1 (en) 2014-08-21
NZ722902A (en) 2017-12-22
SG10201912312YA (en) 2020-02-27
EP3739595A2 (en) 2020-11-18
MX2019007814A (es) 2019-09-05
EP2809812A4 (en) 2016-01-27
US20130196321A1 (en) 2013-08-01
AU2018201688B2 (en) 2020-02-27
JP2017113008A (ja) 2017-06-29
EP2809812A1 (en) 2014-12-10
IL254255B (en) 2018-11-29
AU2020202164A1 (en) 2020-04-16
AU2018201688A1 (en) 2018-04-05
MX351626B (es) 2017-10-23
CO7051010A2 (es) 2014-09-10
JP2015511814A (ja) 2015-04-23
ES2812105T3 (es) 2021-03-16
NZ627887A (en) 2016-08-26
CA2863040C (en) 2022-04-19
JP6351112B2 (ja) 2018-07-04
IL262648B (en) 2020-07-30
EP3179393A3 (en) 2017-09-13
AU2020202164B2 (en) 2022-02-10
MX2014009283A (es) 2014-09-11
US20140303002A1 (en) 2014-10-09
JP2019013255A (ja) 2019-01-31

Similar Documents

Publication Publication Date Title
DK3179393T3 (da) Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft
DK3435084T3 (da) Prostatakræftprognose under anvendelse af biomarkører
DK3312749T3 (da) Fremgangsmåder og anordninger til forudsigelse af risiko for prostatacancer og prostatakirtelvolumen
DK3090062T3 (da) Fusionsgener associeret med fremadskridende prostatakræft
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
DK3354748T3 (da) Størrelsesbaseret DNA-analyse til klassificering af cancer
BR112014030410A2 (pt) inibidores de pirazolopirimidona e pirazolopiridona de tanquirase
BR112015002193A2 (pt) anticorpos anti-etbr e imunoconjugados
DE102012109101A8 (de) Füllstandsmessgerät
DE112012005650T8 (de) Risikomesssystem
DE112013002360T8 (de) Reagenzinjektor
DK2876447T3 (da) Fremgangsmåde til detektering af cancer
SG11201510210XA (en) Methods for detecting prostate cancer
BR112015009583A2 (pt) instalação de distribuição de gás.
FR2999415B1 (fr) Sonde endo-ureterale amelioree
DK3608421T3 (da) Fremgangsmåde til screening for colorektal cancer
DK3004875T3 (da) Prædiktiv biomarkør til cancerterapi
DK3572090T5 (da) Korttidsvirkende faktor-vii-polypeptider
DK2841457T3 (da) Antistof imod ROBO4
FR2992364B1 (fr) Turbopompe
SG10201708046YA (en) Nanoprobe-Based Genetic Testing
BR112014017097A8 (pt) sonda de reflexão
FR2991392B1 (fr) Turbopompe
DK3981885T3 (da) Fremgangsmåde til bestemmelse af graden af DNA-methylering
DK2922563T3 (da) Cd44v6-afledte peptider til behandling af metastaserende kræfttyper